This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Teva Pharmaceutical Industries Ltd.

Drug Names(s): omacetaxine mepesuccinate, Ceflatonin, semisynthetic homoharringtonine, sHHT, CGX-635, Tekinex (EU), Omapro

Description: Ceflatonin is a small molecule with established clinical activity as a single agent in hematological malignancies. It affects a number of cellular pathways, including the regulation of genes associated with apoptosis and angiogenesis.

Omacetaxine has a novel mechanism of action, specifically binding to the ribosomal A-site cleft and inhibiting protein translation of short-lived oncoproteins that are upregulated in leukemic cells (particularly Cyclin-D1, Mcl-1 and c-Myc). In addition, pre-clinical research demonstrated that omacetaxine kills human CML stem cells that are known to be insensitive to TKIs.

Deal Structure: ChemGenex and Stragen
In June 2005, ChemGenex and Stragen Pharma announced an international alliance to accelerate the clinical development of Ceflatonin. ChemGenex will exclusively license the global rights to Stragen's manufacturing process and novel analogues. ChemGenex will be responsible for the global clinical development of Ceflatonin, as well as registration andmarketing in North America and Asia-Pacific. Stragen will be responsible for drug production and global supply, as well as facilitating regulatory approvals within Europe. Once Ceflatonin is approved in Europe, the alliance partners will market the product under the ChemGenex brand. The eventual profit splitof sales in this territory will be shared ChemGenex 49%, Stragen 51%.

In June 2008, ChemGenex gained full commercial control of omacetaxine mepesuccinate through an arrangement with its European partner Stragen Pharma to transfer the ownership of Intellectual Property (IP) and commercial rights...See full deal structure in Biomedtracker

Partners: Pfizer Inc.

Synribo News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug